AstraZeneca PLC (ZEGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (ZEGA) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€5.13 Billion ≈ $6.00 Billion USD) by net assets (€45.97 Billion ≈ $53.74 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZEGA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.011x |
|
Roche Holding AG
SW:ROG
|
0.296x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.133x |
|
Wells Fargo & Company
NYSE:WFC
|
0.051x |
|
Roche Holding AG
SW:ROP
|
0.296x |
|
China Construction Bank Corporation
F:C6T
|
0.158x |
|
International Business Machines
NYSE:IBM
|
0.156x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2024)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see ZEGA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €40.87 Billion ≈ $47.78 Billion |
€11.86 Billion ≈ $13.87 Billion |
0.290x | +9.68% |
| 2023-12-31 | €39.17 Billion ≈ $45.79 Billion |
€10.36 Billion ≈ $12.12 Billion |
0.265x | -0.03% |
| 2022-12-31 | €37.06 Billion ≈ $43.32 Billion |
€9.81 Billion ≈ $11.47 Billion |
0.265x | +74.37% |
| 2021-12-31 | €39.29 Billion ≈ $45.93 Billion |
€5.96 Billion ≈ $6.97 Billion |
0.152x | -50.54% |
| 2020-12-31 | €15.64 Billion ≈ $18.28 Billion |
€4.80 Billion ≈ $5.61 Billion |
0.307x | +50.87% |
| 2019-12-31 | €14.60 Billion ≈ $17.06 Billion |
€2.97 Billion ≈ $3.47 Billion |
0.203x | +9.12% |
| 2018-12-31 | €14.04 Billion ≈ $16.42 Billion |
€2.62 Billion ≈ $3.06 Billion |
0.186x | -13.30% |
| 2017-12-31 | €16.64 Billion ≈ $19.46 Billion |
€3.58 Billion ≈ $4.18 Billion |
0.215x | -13.54% |
| 2016-12-31 | €16.67 Billion ≈ $19.49 Billion |
€4.14 Billion ≈ $4.85 Billion |
0.249x | +38.46% |
| 2015-12-31 | €18.51 Billion ≈ $21.64 Billion |
€3.32 Billion ≈ $3.89 Billion |
0.180x | -50.01% |
| 2014-12-31 | €19.65 Billion ≈ $22.97 Billion |
€7.06 Billion ≈ $8.25 Billion |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more